George D. Yancopoulos
Co-Founder, President, Chief Scientific Officer & Co-ChairmanDr. George D. Yancopoulos, M.D., Ph.D. has been Co-Founder of Regeneron Pharmaceuticals, Inc. and is its Board Co-Chair since June 2023 and had been its Founding Scientist and has been the Chief Scientific Officer at Regeneron Pharmaceuticals, Inc. since January 1998 and its President since December 16, 2016. He is a Scientific Founder at since 2021. He joined Dr. Schleifer in 1989 as founding scientist of Regeneron and together they built and have managed the Company since then. He served as the President of Regeneron Research Laboratories, a subsidiary of Regeneron Pharmaceuticals, Inc. from December 2000 to December 2016. He served as Executive Vice President of Regeneron Pharmaceuticals, Inc. since December 2000. He served as the Senior Vice President, Research of Regeneron Research Laboratories, a position he held since June 1997 and Chief Scientific Officer, since January 1998. He served as Vice President, Discovery from January 1992 to June 1997, Head of Discovery from January 1991 to January 1992 and Senior Staff Scientist from March 1989 to January 1991 for Regeneron Research Laboratories. He has been a Director of Regeneron Pharmaceuticals, Inc. since 2001. He serves as a Member of the Advisors Board of Plain Sight Systems. In 2004, he was elected to be a Member of the National Academy of Sciences. He, together with key Members of his team, is a Principal inventor and/or developer of the six FDA-approved drugs the Company has developed, EYLEA® (aflibercept) Injection, PRALUENT® (alirocumab) Injection, DUPIXENT® (dupilumab) Injection, KEVZARA® (sarilumab) Injection, ZALTRAP® (ziv-aflibercept) Injection for Intravenous Infusion and ARCALYST® (rilonacept) Injection for Subcutaneous Use, as well as of its foundation technologies, including the TRAP technology, VelociGene® and VelocImmune®. As one of the few Members of the National Academy of Sciences from industry and as an author of a substantial number of scientific publications, he has a distinguished record of scientific expertise. In 1997 survey by the Institute for Scientific Information, he was listed among the 11 most highly cited scientists and was the only non-academic scientist in that group. He received his Ph.D. in Biochemistry and Molecular Biophysics and his M.D. from Columbia University. He completed Bachelor of Arts in Biochemistry at Columbia College.
Positions
- Company NameRegeneron Pharmaceuticals, Inc.Stock CodeREGNPositionCo-Founder, President, Chief Scientific Officer & Co-ChairmanColleagues
- LSLeonard S. SchleiferCo-Founder, President, CEO & Co-Chairman
- CRChristopher R. FenimoreExecutive VP of Finance & CFO
- JJJoseph J. LaRosaExecutive VP, General Counsel & Secretary
- AJAndrew J. MurphyExecutive VP of Research & Co-Chief Scientific Officer
- GLGeorge L. SingIndependent Director
- CAChristine Ann PoonLead Independent Director
- JLJoseph L. GoldsteinIndependent Director
